Icatibant PSK

Home page
Medications
Icatibant PSK

Rare Diseases

Icatibant PSK

Registration certificate:

LP-006350

INN:

Icatibant

Release form:

Solution for subcutaneous injection

Therapeutic Area:

Rare Diseases

Pharmacotherapeutic Group:

Bradykinin B2-receptor selective antagonist

Conditions for dispensing:

On prescription

Packaging:

Indications for Use:

Icatibant PSK is indicated for the symptomatic treatment of acute attacks of hereditary angioedema (caused by C1-esterase inhibitor deficiency) in adults, adolescents, and children aged 2 years and older.